AstraZeneca PLC
AZN
$171.34
-$1.96-1.13%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 25.93% | 33.67% | 45.34% | 44.71% | 28.80% |
| Total Depreciation and Amortization | 10.72% | 9.26% | 8.25% | -12.07% | 3.92% |
| Total Amortization of Deferred Charges | 18.00% | 18.00% | 18.00% | -28.57% | -28.57% |
| Total Other Non-Cash Items | -199.18% | -117.22% | -126.21% | 272.26% | 181.72% |
| Change in Net Operating Assets | -67.04% | -98.03% | -27.32% | 27.23% | -333.26% |
| Cash from Operations | 2.32% | 8.66% | 22.88% | 33.58% | 21.00% |
| Capital Expenditure | -37.01% | -51.24% | -46.05% | -42.56% | -34.69% |
| Sale of Property, Plant, and Equipment | 25.00% | 566.67% | -76.36% | -77.78% | -79.66% |
| Cash Acquisitions | 23.58% | 64.80% | 67.48% | 66.94% | 68.77% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -57.79% | -95.98% | -19.41% | -15.29% | -18.72% |
| Cash from Investing | -34.59% | -7.73% | 14.69% | 16.92% | 20.14% |
| Total Debt Issued | 289.95% | 123.30% | -94.16% | -88.49% | -90.01% |
| Total Debt Repaid | -101.00% | 51.79% | 51.97% | 92.14% | 46.13% |
| Issuance of Common Stock | 12.82% | 5.00% | 5.26% | 11.11% | 8.33% |
| Repurchase of Common Stock | -21.05% | -14.11% | -543.21% | -527.16% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 0.75% | 0.71% | -7.32% | -7.41% | -10.62% |
| Other Financing Activities | -458.25% | -453.33% | 76.79% | 109.30% | 111.61% |
| Cash from Financing | -9.86% | 47.66% | -88.79% | -36.42% | -216.19% |
| Foreign Exchange rate Adjustments | -230.77% | 113.64% | 149.46% | 26.92% | 120.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -705.07% | 192.84% | 229.33% | 2,080.98% | -70.56% |